T. Rowe Price Investment Management Reduces $14M in Elanco Animal Health Incorporated ($ELAN)
Key Points
- T. Rowe Price Investment Management changed its Elanco Animal Health Incorporated ($ELAN) stake by 1.7% last quarter, cutting to 34,635,086 shares worth $837.13 million.
- Wall Street's consensus rating on $ELAN is Strong Buy and an average price target of $29.79.
- $ELAN last traded around $24.17.
T. Rowe Price Investment Management trimmed its position in Elanco Animal Health Incorporated ($ELAN) by 1.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,635,086 shares of Elanco Animal Health Incorporated after selling 592,332 shares during the quarter. T. Rowe Price Investment Management's holdings in Elanco Animal Health Incorporated were worth $837.13 million as of its most recent filing.
Elanco Animal Health Incorporated ($ELAN) Stock
Elanco Animal Health Incorporated Earnings
Analysts Set New Price Targets
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.